Navigation Links
Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
Date:7/29/2008

y and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward- looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable la
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
2. ThreeWire Expands Presence in the Pharmaceutical Arena
3. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
4. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
7. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
8. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
9. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
10. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
11. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/z54c4k/biomedical ) ... Refrigerators and Freezers Market - Global Industry Analysis, ... 2022" report to their offering. ... has been segmented based on applications: hospitals, research ... The others segment includes applications of biomedical refrigerators ...
(Date:7/28/2015)... July 28, 2015 Deerfield Management Company, L.P. ... Fund, L.P., which will invest in groundbreaking advancements in ... diseases, cancer, and orphan diseases. The venture capital fund ... therapeutics are developed and improve the way healthcare is ... the largest healthcare-focused venture funds in the sector, will ...
(Date:7/28/2015)... DIEGO , July 28, 2015  Kerastem Technologies ... approval from the U.S. FDA Center For Biologics Evaluation ... Therapies to conduct a clinical trial investigating the safety ... of female and early male pattern baldness (androgenic alopecia). ... STYLE trial, follows initial clinical work in ...
(Date:7/28/2015)... BEACH, Calif. , July 28, 2015 /PRNewswire-USNewswire/ ... announced that it has hit a milestone of ... Signafuse was FDA 510(k) cleared in early 2014 ... use in posterolateral spine fusion procedures.  This is ... products, as less than 6% of new synthetic ...
Breaking Biology Technology:Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2Revolutionary Bone Graft Exceeds Expectations 2
... to Focus on Critical Industry Issues -- DUBAI, UAE, September 8, 2010 ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... researchers has completed the majority of the genome sequence ... efforts of Virginia Tech faculty members. The research ... Turkey ( Meleagris gallopavo ): Genome Assembly and Analysis" ... of Science) on Sept. 7, 2010. "To date, ...
... YORK, Sept. 7 Reportlinker.com announces that a new ... Proteomics - Technologies, Markets and Companies ... report describes and evaluates the proteomic technologies that will ... and practice of medicine in the post-genomic era - ...
Cached Biology Technology:Cold Chain MENA 2010 to Focus on Critical Industry Issues 2Cold Chain MENA 2010 to Focus on Critical Industry Issues 3Cold Chain MENA 2010 to Focus on Critical Industry Issues 4Cold Chain MENA 2010 to Focus on Critical Industry Issues 5Cold Chain MENA 2010 to Focus on Critical Industry Issues 6Virginia Tech researchers contribute to turkey genome sequencing 2Virginia Tech researchers contribute to turkey genome sequencing 3Reportlinker Adds Proteomics - Technologies, Markets and Companies 2Reportlinker Adds Proteomics - Technologies, Markets and Companies 3Reportlinker Adds Proteomics - Technologies, Markets and Companies 4Reportlinker Adds Proteomics - Technologies, Markets and Companies 5Reportlinker Adds Proteomics - Technologies, Markets and Companies 6Reportlinker Adds Proteomics - Technologies, Markets and Companies 7Reportlinker Adds Proteomics - Technologies, Markets and Companies 8Reportlinker Adds Proteomics - Technologies, Markets and Companies 9Reportlinker Adds Proteomics - Technologies, Markets and Companies 10Reportlinker Adds Proteomics - Technologies, Markets and Companies 11Reportlinker Adds Proteomics - Technologies, Markets and Companies 12Reportlinker Adds Proteomics - Technologies, Markets and Companies 13Reportlinker Adds Proteomics - Technologies, Markets and Companies 14Reportlinker Adds Proteomics - Technologies, Markets and Companies 15Reportlinker Adds Proteomics - Technologies, Markets and Companies 16Reportlinker Adds Proteomics - Technologies, Markets and Companies 17Reportlinker Adds Proteomics - Technologies, Markets and Companies 18Reportlinker Adds Proteomics - Technologies, Markets and Companies 19Reportlinker Adds Proteomics - Technologies, Markets and Companies 20
(Date:6/30/2015)... YORK , June 30, 2015 To bolster ... security provider HYPR Corp. announced today the addition of two ... will serve as board advisor and David Raviv ... the team underscore HYPR Corp.,s commitment to providing the most ... Dimitri Sirota co-founded Layer 7 Technologies, a provider ...
(Date:6/25/2015)... June 25, 2015  Imagine a tool specifically designed ... healthier, happier life. That,s exactly what USANA,s True ... The cutting-edge, portable health program provides a personalized approached ... help improve your lifestyle and nutrition. ... gala Wednesday night, USANA,s THA was honored with the ...
(Date:6/24/2015)... , June 22, 2015 ... the addition of the "Huawei Ascend Mate ... report to their offering. Huawei,s technological ... the opposite direction than Apple,s and Samsung,s one. ... sensor developed by Fingerprint Cards, a main actor ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... 2013  Pfenex Inc. today announced that the Department of ... Research and Development Authority (BARDA), has modified its prime ... existing Pfenex contractual relationship begun in July, 2010. This ... support the development of a next generation rPA-based anthrax ...
... Resveratrol, a naturally occurring polyphenol compound produced by the ... red wine, has been touted as a beneficial supplement ... been supported by some experimental studies, whereas others suggest ... multiple sclerosis (MS) models published in The American ...
... Sept. 30, 2013 /PRNewswire-iReach/ -- Clinilabs, a contract research ... services to industry, announced today that they have begun ... medication for Type 2 Diabetes Mellitus.  The study is ... multiple daily doses of the investigational medication over periods ...
Cached Biology News:Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine 2Resveratrol, found in red wine, worsens MS-like symptoms and neuropathology in mice 2Resveratrol, found in red wine, worsens MS-like symptoms and neuropathology in mice 3Leading Pharma Company Selects Clinilabs to Conduct a Phase 1 Study of an Investigational Type 2 Diabetes Medication 2
... RNase H degrades, as an endoribonuclease, ... DNA hybrids of natural origin, e.g. ... synthetic complexes, e.g. poly(A) x poly(dT). ... and 3-OH termini. Nearly no activity ...
Unit Definition: 1 U corresponds to the amount of enzyme which produces 1 mol protons per minute at pH 5.5 and 30C (peptin from citrus peel, Fluka-No. 76280, as substrate)...
Recorder, 6", 7 Day, 1 Pen, 0 to 100°C, 220V, 50/60 Hz, for 4520, Customer Installed...
... detection systems provide linking and labelling ... species specific primary antibodies for visualising ... is accomplished using an ultra-sensitive indirect ... labelling technology. Secondary antibodies are polymerised ...
Biology Products: